Physician profile
Dean M Pollock
NPI 1700880259
$1,078.87
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $88.71 · 2021: $288 · 2022: $482.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiovascular Systems INC. | $612.72 | 2019-2022 | |
| Shockwave Medical, INC | $134.42 | 2022 | |
| Medtronic, INC. | $88.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $54.28 | 2019-2020 | |
| Boston Scientific Corporation | $49.74 | 2019-2020 | |
| Abbott Laboratories | $47.84 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $21.81 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.87 | 2019 | |
| Chiesi USA, INC. | $19.36 | 2021 | |
| Amgen INC. | $17.76 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.95 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.